MP Corporate Finance acted as the exclusive financial advisor to the shareholders of Pharmacelsus GmbH, a leading German preclinical contract research organisation, in the sale of Pharmacelsus to GBA Group, backed by Quadriga Capital.
Pharmacelsus, founded in year 2000, is Germany´s market-leading early stage contract research organization (CRO). The company specializes in project-critical testing services for small molecules and peptides.
Pharmacelsus’ service portfolio comprises the complete drug discovery and development testing program (in vitro, in vivo, ex vivo) as well as G(C)LP and non-GLP bioanalysis. The company is located in Saarbrucken, near the French border and serves life science companies and academic institutions in all major European pharma markets and the US.
The GBA Group is a leading lab service provider with 12 subsidiaries in the Germanic region. The company is backed by Quadriga Capital. With this transaction, GBA strengthens its growing Pharmaceutical division. Both companies expect to benefit from synergies due to substantial cross-selling opportunities and operational benefits.
MP Corporate Finance supported Pharmacelsus’ shareholders during the entire process. The transaction team executed a detailed successor analysis and prepared all process-related documents. MPCF managed communications with investors and took the commercial lead in SPA negotiations. MP Corporate Finance executed a swift and tailored M&A process, drawing on extensive transaction experience and deep pharmaceutical industry know-how.